跳至主要内容
临床试验/NCT07026240
NCT07026240招募中不适用

Post-operative Monitoring of Gastric Cancer Using Circulating DNA in Blood Samples

Suzhou Huhu Health & Technology Inc.1 个研究点 分布在 1 个国家目标入组 258 人开始时间: 2024年2月18日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
258
试验地点
1
主要终点
The performance of the new biomarkers in the post-operative monitoring of gastric cancer

研究概览

简要总结

This study is to determine the performance of non-invasive new multi-target biomarkers in the post-operative monitoring of gastric cancer.

详细描述

This study aims to develop and validate a new non-invasive detection method for postoperative monitoring of gastric cancer in the blood. Blood will also be collected at various time points post-operatively. We will determine whether these new biomarkers can be used as prognostic biomarkers to predict tumor recurrence and metastasis. We will also determine whether these new biomarkers detect tumor recurrence and metastasis earlier than methods currently used in the clinic such as imaging and tumor biomarkers CA19-9, CEA, and CA72-4.

This study is a prospective and multi-center study.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject age over
  • Subject has stomach discomfort, and seek medical attention at the Gastric Surgery Department of our center.
  • Subject has or will have gastroscopy and/or pathological examination results at this center.
  • Subject must be able to fully understand the informed consent form and be able to personally sign it.

排除标准

  • Subject has serious heart, liver, kidney dysfunction, or mental illness.
  • Subject diagnosed previously with any kind of malignant tumor.
  • Subject is known to be infected with HIV or other related diseases (considering interference from the use of immune drugs).
  • Subject is receiving targeted drugs, immunosuppressants, immunomodulators, and biological therapies.
  • Researchers believe that subject is not suitable for enrollment.
  • Subject can not supply sufficient sample to complete this experiment.

结局指标

主要结局

The performance of the new biomarkers in the post-operative monitoring of gastric cancer

时间窗: 2 years

Number of Participants With Tumor Recurrence Detected by the New System vs. Imaging and Serum Markers (CA19-9, CEA, CA72-4).

次要结局

  • Metastasis Detection Time: New vs. Conventional Methods(2 years)

研究者

发起方
Suzhou Huhu Health & Technology Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验